DFTX ▲ +1.2% - Definium Therapeutics, Inc. $DFTX Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results Definium Therapeutics shares rose 1.2% after the company announced that its LSD-based treatment candidate DT120 received Breakthrough Therapy designation from the FDA for major depressive disorder, following positive Phase 3 trial results. Breakthrough designation accelerates the regulatory review timeline and typically signals FDA confidence in a candidate's potential to address unmet medical needs, which can de-risk the path to commercialization for the company's lead program. 08-SEP-2026 07:00 AM ET